3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Paclitaxel
18
pembrolizumab
16
Cisplatin
16
Fluorouracil
15
Irinotecan
13
tislelizumab
9
Oxaliplatin
8
Nivolumab
8
Docetaxel
8
Leucovorin
6
Capecitabine
5
spartalizumab
4
Levoleucovorin
4
Carboplatin
4
lenvatinib
3
durvalumab
3
Radiotherapy
3
Drug Therapy
3
toripalimab
2
sintilimab
2
regorafenib
2
elgemtumab
2
atezolizumab
2
Itraconazole
2
Injections
2
Gemcitabine
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
sitravatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Squamous Cell Carcinoma
×
Histamine Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled